(New York, NY, October 22, 2015) -- New York Blood Center, a nonprofit, community-based organization that serves more than 20 million people and 200 hospitals in the New York metropolitan area, today announced that it has added a new Trustee to its board. Several additional board changes were confirmed as well at the organization's annual meeting this week, including the return of 18 of its 20 current Trustees for the coming year.
The changes come as NYBC approaches its bi-annual Gala, to be held on November 5, 2015, in a year when the organization has seen its donations soar, particularly through the summer months. In August, NYBC announced a partnership with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for the repair and regeneration of retina, kidney, lung and liver tissue, as well as for the treatment of neurodegenerative disorders such as Parkinson's, Alzheimer's and Huntington's disease. It was subsequently announced that this effort will be joined by Drs. Peter Wernet of Dusseldorf University and Hans Schöler of the Max Planck Institute, Münster, working with the Good Manufacturing Practices (GMP) Labs of RheinCell Therapeutics. This collaboration will further the goal of promoting regenerative medicine, a new frontier that will enable doctors to repair or replace virtually every major organ in the human body.
Joining the Board is Philip Falivene, who has for many years helped coordinate blood donations at Bank of New York Mellon in New York. Mr. Falivene is a Managing Director and the Head of Public Finance Global Client Management at the bank. He has 25 years of banking and management experience, including service at Chase Manhattan and Chemical Bank. Mr. Falivene earned his MBA at New York University’s Stern School of Business.
William H. Crouse, who has been a board member since 1994, will move to Trustee Emeritus status. Among his other responsibilities, Mr. Crouse served for a period as Chair of NYBC’s strategic planning committee.
“Bill Crouse has been crucial to the success of our organization, which serves tens of millions of people in the greater New York area,” said Howard P. Milstein, Chairman of NYBC. “NYBC saves lives every day, and Bill’s wisdom and experience has been a large part of our growth and development. We look forward to continuing our working relationship in Bill’s new role of Trustee emeritus.”
Dr. Laurie Glimcher, Dean of Weill Cornell Medical Center, finished her term as a Trustee on October 21, 2015, having fulfilled her commitment.
Dr. Glimcher said: “For the past three years, I have proudly served on the board of the New York Blood Center, an organization committed to the critical mission of life-saving blood collection and distribution, as well as prevention of HIV infection, advancements in hematology and transfusion medicine, and developments in stem cell biology and regenerative medicine. It has been an honor to be associated with such a remarkable institution.”
Mr. Milstein said: “We thank Dr. Glimcher for her service to the board, particularly her crucial insight and contributions in the areas of research and the development of new blood-related technologies that hold the promise of saving even more lives in the years to come.”
About New York Blood Center
Now more than 50 years old, New York Blood Center (NYBC) is one of the largest independent, nonprofit community-based blood centers in the country, serving the more than 20 million people who live in the New York metropolitan area. Each year, NYBC provides approximately one million blood products to nearly 200 hospitals in the Northeast. In addition, NYBC's Community Blood Center of Greater Kansas City (CBC) serves hospitals in the Kansas City metropolitan area, as well as eastern Kansas and western Missouri. CBC provides nearly 200,000 blood products per year to approximately 70 area hospitals.
NYBC also provides a wide array of transfusion-related medical services. NYBC is also home to the world's largest public cord blood bank, which provides stem cells for transplant in many countries, and a renowned research institute, which-among other milestones-developed the Hepatitis B vaccine and innovative blood purification technology. More information can be found at www.nybloodcenter.org.